Nina Shah, MD, discusses the question of whether CAR T-cell therapy is ready for primetime in patients with multiple myeloma.
Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the question of whether chimeric antigen receptor (CAR) T-cell therapy is ready for primetime in patients with multiple myeloma.
Shah says it is not primetime for CAR T cells in multiple myeloma yet, but the reason for asking this question is because of the significant responses that have been demonstrated with CAR T cells already in this space. The therapy induced response rates around 85% to 90% in patients who are heavily pretreated with multiple myeloma, where the median number of prior lines is 7. These kind of response rates are unheard of in this patient population, Shah says, and CAR T-cell therapy is ultimately rescuing a lot of really sick patients.
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More